| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/10/2002 | WO2002002147A2 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | WO2002002146A2 Dextrin-amphotericin conjugates and their methods of preparation |
| 01/10/2002 | WO2002002145A2 Composition for aqueous stabilization of fat-soluble vitamins |
| 01/10/2002 | WO2002002136A1 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
| 01/10/2002 | WO2002002132A1 Chemokine conjugates |
| 01/10/2002 | WO2002002125A1 Injectable composition |
| 01/10/2002 | WO2002002124A1 Compositions containing ascorbic acid phosphoric acid esters |
| 01/10/2002 | WO2002002110A1 Use of indole-3-acetic acid derivatives in medicine |
| 01/10/2002 | WO2002002102A1 Rapid fatty acid delivery |
| 01/10/2002 | WO2002002095A2 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 01/10/2002 | WO2002002085A2 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities |
| 01/10/2002 | WO2002002084A1 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| 01/10/2002 | WO2002002083A1 Tablet rapidly disintegrating in mouth and process for producing the same |
| 01/10/2002 | WO2002002079A1 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 01/10/2002 | WO2002002078A2 Improved liposomal camptothecins and uses thereof |
| 01/10/2002 | WO2002002077A2 Liposomal antineoplastic drugs and uses thereof |
| 01/10/2002 | WO2002002076A2 Methods for treating inflammation-mediated conditions of the eye |
| 01/10/2002 | WO2002002059A1 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 01/10/2002 | WO2002002056A2 Method of treatment of seborrheic dermatitis |
| 01/10/2002 | WO2001070291A3 Injectable microspheres for dermal augmentation and tissue bulking |
| 01/10/2002 | WO2001056611B1 Oral delivery of allergens in milk |
| 01/10/2002 | WO2001052900A3 Novel orthogonally protected amino acid chelators for biomedical applications |
| 01/10/2002 | WO2001051066A3 Reduction in bacterial colonization by administering bacteriophage compositions |
| 01/10/2002 | WO2001051027A3 Polymer blends as biodegradable matrices for preparing biocomposites |
| 01/10/2002 | WO2001043762A3 Polypeptide compositions with improved stability |
| 01/10/2002 | WO2001037896A3 Methods and compositions for administration of therapeutic reagents |
| 01/10/2002 | WO2001037721A3 Magnetic nanoparticles for selective therapy |
| 01/10/2002 | WO2001035927A3 Topical application of muscarinic analgesic drugs such as neostigmine |
| 01/10/2002 | WO2001034118A3 Solid dispersion pharmaceutical formulations |
| 01/10/2002 | WO2001032616A3 Oxetanone derivatives |
| 01/10/2002 | WO2001030804A3 Salt form of a conjugate useful in the treatment of prostate cancer |
| 01/10/2002 | WO2001030408A3 Adhesive composition over a bioactive polymerization initiator |
| 01/10/2002 | WO2001028593A3 Conjugates useful in the treatment of prostate cancer |
| 01/10/2002 | WO2001028494A3 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 01/10/2002 | WO2001025410A3 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 01/10/2002 | US20020004942 Transgenic plant that expresses luciferase; for use in the development of toys, foods, textiles and beverages that glow |
| 01/10/2002 | US20020004678 Surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents |
| 01/10/2002 | US20020004584 HIV immune adjuvant therapy |
| 01/10/2002 | US20020004579 Preparation of a therapeutic composition |
| 01/10/2002 | US20020004532 Low emulsifier multiple emulsions |
| 01/10/2002 | US20020004529 Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| 01/10/2002 | US20020004506 In binder film |
| 01/10/2002 | US20020004486 Miticides, parasiticides; veterinary medicine |
| 01/10/2002 | US20020004484 Topical anesthetic/opioid formulations and uses thereof |
| 01/10/2002 | US20020004483 Polypeptides, genetic engineering |
| 01/10/2002 | US20020004478 Pharmaceutical formulations for igf/igfbp |
| 01/10/2002 | US20020004240 Method and system for introducing a gene into a human stem cell |
| 01/10/2002 | US20020004208 Generating nicotine antibodies in situ |
| 01/10/2002 | US20020004202 In vivo screen using chemical inducers of dimerization |
| 01/10/2002 | US20020004101 Drug coating with topcoat |
| 01/10/2002 | US20020004063 Methods and apparatus for drug delivery involving phase changing formulations |
| 01/10/2002 | US20020004061 Target binding, cavities forming, drugs |
| 01/10/2002 | US20020004047 DNA encoding a novel RG1 polypeptide |
| 01/10/2002 | US20020003179 Forming a dispersion of solid particles of a milled substrate in a fluid carrier comprising providing large size milling media and small size milling media, a conglomerate of solid comprising a substrate to be milled, milling, separating |
| 01/10/2002 | US20020002933 Replacing conventional industrial solvents with dimethyl carbonate or methyl pivalate which have a low reactivity with respect to ozone formation |
| 01/10/2002 | DE10030345A1 Hochkonzentrierte stabile Meloxicamlösungen Highly concentrated stable meloxicam |
| 01/10/2002 | CA2414966A1 A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component |
| 01/10/2002 | CA2414650A1 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | CA2414355A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | CA2413237A1 Alteration of cell membrane for new functions |
| 01/10/2002 | CA2410972A1 Compounds to treat alzheimer's disease |
| 01/10/2002 | CA2410680A1 Compounds to treat alzheimer's disease |
| 01/10/2002 | CA2407910A1 Antibodies that immunospecifically bind to blys |
| 01/09/2002 | EP1170592A1 Presentation of hydrophobic antigens to T-cells by CD1 molecules |
| 01/09/2002 | EP1170373A1 Peptide-mediated ocular cell transfection |
| 01/09/2002 | EP1170018A1 Ligand-bonded complex |
| 01/09/2002 | EP1170006A1 Drugs for relieving hemicrania |
| 01/09/2002 | EP1170004A1 Preparations for percutaneous absorption |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169378A1 Preparing porous hydrogel products |
| 01/09/2002 | EP1169349A2 Highly purified gonadotropin compositions and process for preparing them |
| 01/09/2002 | EP1169318A1 Prodrugs of thrombin inhibitors |
| 01/09/2002 | EP1169244A2 Metering valve |
| 01/09/2002 | EP1169069A1 Three-dimensional stromal tissue |
| 01/09/2002 | EP1169064A2 Method of detecting endometriosis |
| 01/09/2002 | EP1169063A2 Treatment of intracellular infection |
| 01/09/2002 | EP1169062A2 Heat stable coated colloidal iron oxides |
| 01/09/2002 | EP1169053A1 Pulmonary administration of dry powder formulations for treating infertility |
| 01/09/2002 | EP1169050A1 Ocular treatment using cyclosporin-a derivatives |
| 01/09/2002 | EP1169046A1 Pulmonary delivery of protonated/acidified nucleic acids |
| 01/09/2002 | EP1169039A2 Pharmaceutical formulation comprising amoxycillin |
| 01/09/2002 | EP1169033A2 Enhanced tissue and subcellular delivery of vitamin e compounds |
| 01/09/2002 | EP1169026A2 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1169024A1 Pregelatinized starch in a controlled release formulation |
| 01/09/2002 | EP1169023A1 Solubilizing aids in powder form for solid pharmaceutical presentation forms |
| 01/09/2002 | EP1169021A1 Compositions and methods for treating lymphoma |
| 01/09/2002 | EP1169020A1 Lipid aggregate forming compositions and their uses |
| 01/09/2002 | EP1169019A1 Pharmaceutical aerosol formulation |
| 01/09/2002 | EP1168934A1 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 01/09/2002 | EP1073463A4 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| 01/09/2002 | EP1049461B1 Use of topical preparations of glyceryl trinitrate and lanolin for the treatment of erectile dysfunction |
| 01/09/2002 | EP0949909B1 Individually dosed foil-form presentation which decomposes rapidly on contact with liquid and contains an active substance, in particular an aromatic substance |
| 01/09/2002 | EP0804172B1 Controlled release potassium dosage form |
| 01/09/2002 | EP0785795B1 A pharmaceutical formulation comprising a growth hormone and valine |
| 01/09/2002 | EP0765151B1 Antibacterial oil-in-water emulsions |
| 01/09/2002 | EP0727978B1 Topical aromatic releasing compositions |
| 01/09/2002 | CN1330610A Silicon dioxide with mesopores and micropores |
| 01/09/2002 | CN1330552A Oral vaccine against diarrhea |
| 01/09/2002 | CN1330551A Pharmaceutical formulation of Didemnin compound |